Cheng Peng,Alastair G. Stewart,Owen L. Woodman,Rebecca H. Ritchie,Cheng Xue Qin
Abstract:Non-alcoholic steatohepatitis (NASH) develops from non-alcoholic fatty liver disease (NAFLD). Currently, around 25% of the population is estimated to have NAFLD, and 25% of NAFLD patients are estimated to have NASH. NASH is typically characterized by liver steatosis inflammation, and fibrosis driven by metabolic disruptions such as obesity, diabetes, and dyslipidemia. NASH patients with significant fibrosis have increased risk of developing cirrhosis and liver failure. Currently, NASH is the second leading cause for liver transplant in the United States. More importantly, the risk of developing hepatocellular carcinoma from NASH has also been highlighted in recent studies. Patients may have NAFLD for years before progressing into NASH. Although the pathogenesis of NASH is not completely understood, the current “multiple-hits” hypothesis suggests that in addition to fat accumulation, elevated oxidative and ER stress may also drive liver inflammation and fibrosis. The development of clinically relevant animal models and pharmacological treatments for NASH have been hampered by the limited understanding of the disease mechanism and a lack of sensitive, non-invasive diagnostic tools. Currently, most pre-clinical animal models are divided into three main groups which includes: genetic models, diet-induced, and toxin + diet-induced animal models. Although dietary models mimic the natural course of NASH in humans, the models often only induce mild liver injury. Many genetic and toxin + diet-induced models rapidly induce the development of metabolic disruption and serious liver injury, but not without their own shortcomings. This review provides an overview of the “multiple-hits” hypothesis and an evaluation of the currently existing animal models of NASH. This review also provides an update on the available interventions for managing NASH as well as pharmacological agents that are currently undergoing clinical trials for the treatment of NASH.
What problem does this paper attempt to address?
This paper aims to review the mechanisms, animal models, and medical treatments of non-alcoholic steatohepatitis (NASH). Specifically:
1. **Disease Background**: The paper first introduces the basic situation of NASH and its epidemiological characteristics. NASH is a type of non-alcoholic fatty liver disease (NAFLD), characterized by excessive fat accumulation, inflammation, and fibrosis in the liver. Currently, about 25% of the global population has NAFLD, and approximately 25% of these patients will develop NASH. NASH is one of the leading causes of cirrhosis and liver failure.
2. **Diagnostic Methods**: The paper discusses the existing diagnostic methods for NASH, including transaminase levels (ALT and AST) in blood tests, imaging examinations (such as CT and MRI), and liver biopsy. However, these methods have certain limitations, especially the invasive nature of liver biopsy.
3. **Pathogenesis**: The paper elaborates on the "multiple hit" hypothesis of NASH, which suggests that in addition to fat accumulation, oxidative stress and endoplasmic reticulum stress may also drive the development of hepatitis and fibrosis. Moreover, factors such as obesity, insulin resistance, and dyslipidemia are closely related to the occurrence of NASH.
4. **Genetic Factors**: The paper points out that genetic factors play an important role in the development of NASH. For example, gene variants (such as TM6SF2, GCKR, and PNPLA3) are associated with susceptibility to NASH.
5. **Metabolic Factors**: Obesity and systemic insulin resistance are considered important triggers for NASH. High-fat diets and high-sugar diets can also promote fat accumulation in the liver, leading to fatty liver.
6. **Oxidative Stress and Endoplasmic Reticulum Stress**: The paper emphasizes the role of oxidative stress and endoplasmic reticulum stress in NASH. Excessive oxidative stress can lead to hepatocyte damage and apoptosis, while endoplasmic reticulum stress can activate multiple signaling pathways, ultimately resulting in liver damage.
7. **Existing Animal Models**: The paper evaluates the currently available animal models for NASH, including genetic models, diet-induced models, and toxin + diet-induced models, and discusses their advantages and limitations.
8. **Therapeutic Advances**: Finally, the paper summarizes the currently available treatments for NASH and the drugs undergoing clinical trials.
In summary, this paper aims to provide a comprehensive overview of the pathogenesis, diagnostic methods, animal models, and therapeutic advances of NASH, with the goal of providing a reference for NASH research and treatment.